Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Controls seizures in a pre-eclampsia and eclampsia, respectively. Sold as Magnesium Sulfate, Magnesium Sulfate In Plastic Container, Magnesium Sulfate In Dextrose 5% In Plastic Container. Every FDA application for this active ingredient: 3 branded and 18 generic.
As of Nov 15, 2026, FDA lists 21 applications for Magnesium Sulfate (sold as Magnesium Sulfate, Magnesium Sulfate In Plastic Container, Magnesium Sulfate In Dextrose 5% In Plastic Container), first approved Sep 8, 1986, with 0 new uses approved and 0 published complete response letters.
First approved: Sep 8, 1986
Applications: 21
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $476K
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Magnesium Sulfate
Part D
$272K
+31%
1,296
Magnesium Sulfate
Part B
$204K
-20%
19,451
Clinical Trials
132 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Fresenius Kabi USA
Baxter Hlthcare Corp